Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.83 Insider Own25.80% Shs Outstand21.53M Perf Week-3.61%
Market Cap15.25M Forward P/E- EPS next Y-1.67 Insider Trans0.00% Shs Float2.35M Perf Month8.09%
Income-7.72M PEG- EPS next Q-0.69 Inst Own3.50% Short Float0.65% Perf Quarter45.32%
Sales0.00M P/S- EPS this Y20.71% Inst Trans-61.77% Short Ratio0.54 Perf Half Y-18.39%
Book/sh1.85 P/B2.60 EPS next Y28.34% ROA-79.13% Short Interest0.02M Perf Year-50.57%
Cash/sh1.35 P/C3.57 EPS next 5Y- ROE-95.77% 52W Range2.46 - 10.36 Perf YTD5.25%
Dividend Est.- P/FCF- EPS past 5Y47.54% ROI-132.05% 52W High-53.57% Beta0.33
Dividend TTM- Quick Ratio2.73 Sales past 5Y3.72% Gross Margin- 52W Low95.50% ATR (14)0.40
Dividend Ex-Date- Current Ratio2.73 EPS Y/Y TTM16.96% Oper. Margin0.00% RSI (14)48.10 Volatility6.09% 8.36%
Employees16 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price24.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-322.52% Payout- Rel Volume0.46 Prev Close4.62
Sales Surprise- EPS Surprise55.37% Sales Q/Q- EarningsFeb 09 AMC Avg Volume28.13K Price4.81
SMA20-4.27% SMA500.21% SMA200-4.69% Trades Volume12,922 Change4.16%
Feb-09-24 04:15PM
Jan-04-24 04:15PM
Dec-18-23 05:51AM
Dec-15-23 04:10PM
Nov-20-23 04:05PM
04:05PM Loading…
Oct-26-23 04:05PM
Oct-25-23 09:10AM
Oct-19-23 09:15AM
Oct-12-23 12:15PM
Oct-10-23 09:00AM
Sep-28-23 08:15AM
Aug-16-23 11:40AM
Aug-09-23 04:15PM
Aug-04-23 08:56AM
09:00AM Loading…
Jul-26-23 09:00AM
Jun-28-23 03:55PM
Jun-27-23 08:15AM
Jun-15-23 08:00AM
May-17-23 08:22AM
May-11-23 04:30PM
Apr-20-23 08:30AM
Apr-04-23 08:45AM
Mar-23-23 04:30PM
Mar-16-23 04:10PM
Mar-15-23 08:10AM
Feb-15-23 05:11AM
Feb-12-23 09:00AM
Feb-10-23 09:00AM
08:15AM Loading…
Feb-01-23 08:15AM
Jan-18-23 05:50AM
Jan-17-23 12:30PM
Dec-22-22 06:47AM
Dec-20-22 08:30AM
Dec-16-22 09:00AM
Dec-02-22 08:00AM
Nov-03-22 09:00AM
Oct-03-22 11:10AM
Sep-30-22 08:00AM
Sep-08-22 04:30PM
Sep-07-22 08:00AM
Aug-24-22 07:15AM
Aug-12-22 04:30PM
Aug-03-22 08:15AM
Jul-16-22 08:11AM
Jul-11-22 08:30AM
May-24-22 01:04PM
May-19-22 04:30PM
May-17-22 08:43AM
May-13-22 08:55AM
Apr-28-22 07:45AM
Mar-29-22 09:00AM
Mar-24-22 04:30PM
Mar-22-22 08:00AM
Feb-18-22 07:05AM
Feb-17-22 08:00AM
Feb-14-22 09:00AM
Feb-06-22 07:42AM
Jan-26-22 07:45AM
Jan-13-22 09:55AM
Jan-06-22 05:28AM
Dec-28-21 04:15PM
Dec-08-21 06:34AM
Dec-01-21 07:58AM
Nov-04-21 08:00AM
Oct-21-21 10:16AM
Oct-19-21 09:32AM
Oct-09-21 10:29AM
Sep-22-21 04:46AM
Sep-20-21 02:43PM
Sep-09-21 07:00AM
Sep-01-21 10:30AM
Aug-26-21 01:01PM
Aug-13-21 07:50AM
Aug-05-21 02:00AM
Jul-13-21 08:10AM
Jun-24-21 02:50AM
Jun-23-21 07:55AM
Jun-18-21 08:50AM
Jun-08-21 08:00AM
Jun-04-21 06:52AM
Jun-03-21 08:47AM
May-28-21 08:00AM
May-18-21 08:27AM
May-14-21 08:00AM
Apr-22-21 08:00AM
Mar-26-21 11:14AM
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.